The massive potential dilution from this ELOC (up to 89% of shares outstanding) and the deeply discounted pricing mechanism (5%+ below market) create a powerful downward overhang on JAGX. Traders should expect continued selling pressure as C/M Capital resells shares into the market. The company's going-concern status and history of repeated dilutive financings suggest this is a distressed capital raise, not a growth catalyst. Avoid long positions and consider monitoring for further deterioration.
Executive Summary
Jaguar Health filed a pre-effective amendment (S-1/A) to register up to 41,000,000 shares for resale by C/M Capital Master Fund, LP under a $40 million equity line of credit (ELOC) established June 9, 2026. The company will not receive proceeds from the resale but may draw up to $40M from the ELOC at its discretion, with shares sold at a 5%+ discount to market. This filing, combined with a $2M Series P Preferred Stock financing on the same date, signals severe capital needs for a micro-cap biotech with a going-concern audit opinion, and the massive potential dilution (up to 89% of outstanding shares) is profoundly bearish for existing common stockholders.
Key Facts
- Registers up to 41,000,000 shares for resale by C/M Capital Master Fund, LP under a $40M ELOC (Purchase Agreement dated June 9, 2026).
- Company may sell shares to C/M Capital at a minimum 5% discount to market price (VWAP Purchase Price = 95% of lowest of VWAP, 5-day low, or closing price).
- As of July 10, 2026, only 4,910,402 shares were outstanding; the 41M registered shares represent potential dilution of over 89% of total shares outstanding.
- Company also completed a $2.0M Series P Non-Convertible Preferred Stock private placement on June 9, 2026, with the same selling stockholder.
- Auditor's report includes a going-concern explanatory paragraph; the company has a history of repeated dilutive financings (16 offering/registration filings in 24 months).
- Company will not receive proceeds from the resale but may receive up to $40M in gross proceeds from future ELOC draws, intended for working capital and redemption of Series P Preferred Stock.
- Stockholder approval for the ELOC was obtained at the reconvened 2026 annual meeting on June 8, 2026.
- On July 14, 2026, the last reported sales price was $2.17 per share, giving a market cap of approximately $10.7M.
Financial Impact
Potential dilution of up to 89% of outstanding shares via a $40M ELOC with shares sold at a 5%+ discount to market, plus a $2M Series P Preferred Stock financing. The company has a going-concern opinion and no revenue or net income figures are provided in this filing.
Risk Factors
- Massive dilution: up to 89% of current shares outstanding could be issued under the ELOC, severely diluting existing holders.
- Discounted pricing: shares sold to C/M Capital at 5%+ below market create immediate selling pressure and a structural downward bias on the stock price.
- Going-concern risk: the independent auditor's report includes an explanatory paragraph regarding the company's ability to continue as a going concern.
- Repeated dilutive financing pattern: 16 offering/registration filings in the last 24 months indicate a systemic reliance on equity dilution for funding.
- Uncertain access to ELOC: the company may not be able to draw the full $40M due to market conditions, stock price falling below the $1.10 floor price, or other conditions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (JAGX) — Batch item 1 | 0001193125-26-315711 |
| Document: d47881dexfilingfees.htm | 0001193125-26-315711 |
| Document: d47881dex51.htm | 0001193125-26-315711 |
| Document: d47881dex231.htm | 0001193125-26-315711 |
| Document: 0001193125-26-315711-index-headers.html | 0001193125-26-315711 |
| Document: 0001193125-26-315711-index.html | 0001193125-26-315711 |
| Document: 0001193125-26-315711.txt | 0001193125-26-315711 |
| S-1/A Filing (JAGX) — Batch item 8 | 0001193125-26-315711 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | S-3 | $2.04 | awaiting T+60 | — | $2.37 (−16.18%) |
Oct 8, 2026 19d ago | DEF 14A | $4.79 | awaiting T+60 | — | $2.37 (+50.52%) |
Oct 5, 2026 22d ago | 8-K | $4.73 | awaiting T+60 | — | $2.37 (+49.89%) |
Sep 28, 2026 29d ago | 8-K | $6.02 | awaiting T+60 | — | $2.37 (+60.63%) |
Sep 24, 2026 4w ago | SC 13G/A | $7.70 | awaiting T+60 | — | $2.37 (+69.22%) |
Sep 24, 2026 4w ago | 424B5 | $7.06 | awaiting T+60 | — | $2.37 (+66.43%) |
Sep 24, 2026 4w ago | 8-K | $7.06 | awaiting T+60 | — | $2.37 (+66.43%) |
Sep 21, 2026 5w ago | 8-K | $34.46 | awaiting T+60 | — | $2.37 (−93.12%) |
Sep 15, 2026 6w ago | 8-K | $0.2246 | awaiting T+60 | — | $2.37 (−955.21%) |
Sep 3, 2026 7w ago | 424B5 | $10.41 | awaiting T+60 | — | $2.37 (+77.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers